• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

7.080 -0.820 (-10.38%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,108,318
Open 7.870
Bid (Size) 7.000 (300)
Ask (Size) 7.160 (400)
Prev. Close 7.900
Today's Range 6.950 - 7.870
52wk Range 6.950 - 17.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Monday's session: top gainers and losers ↗
October 12, 2026
Via Chartmill
What's going on in today's session ↗
October 12, 2026
Via Chartmill

Performance

52-Week Range 60.2% below 52-week high
7.080
6.9552W Low 17.7952W High
1 Week 38.6% below 1-week high
6.951W Low 11.541W High

Contineum Therapeutics, Inc. - Common stock (CTNM) traded between $6.95 and $17.79 over the past 52 weeks and last traded at $7.08, 60.2% below its 52-week high. Over the past week it ranged between $6.95 and $11.54.

Past 12 Months
-17.3%
-47.7%
-47.7%
-47.4%
-37.8%
-36.2%
1W -$1.48
1M -$6.45
3M -$6.45
6M -$6.39
YTD -$4.31
1Y -$4.01

CTNM was -36.2% over the past year, -47.4% over six months, -37.8% year to date, -17.3% in the last week.

12 Months vs Market
CTNM
-36.2%
DIA
+11.2%
SPY
+13.7%
QQQ
+16.1%
IWM
+9.0%

Over the past 12 months CTNM returned -36.2% versus DIA (Dow) +11.2%, SPY (S&P 500) +13.7%, QQQ (Nasdaq 100) +16.1% and IWM (Russell 2000) +9.0%.

Volume & Liquidity 1.51× 3-mo avg
Today 1,108,318 3-mo avg 732.7K
1W
2.9M
1M
1.3M
3M
732.7K
6M
521.8K
YTD
437.0K
1Y
387.9K

CTNM most recently traded 1,108,318 shares against a 3-month average daily volume of 732.7K.

More News

Read More
These stocks are gapping in today's session ↗
October 12, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
October 12, 2026
Via Chartmill
Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗
March 05, 2026
Via Chartmill
What's going on in today's after hours session ↗
September 14, 2026
Via Chartmill
News headline image
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
September 14, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
News headline image
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
August 25, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
These stocks are moving in today's pre-market session ↗
August 13, 2026
Via Chartmill
News headline image
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
July 30, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
June 30, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
June 01, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
May 22, 2026
Via MarketBeat
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
May 11, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
May 05, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
April 30, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
March 05, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
March 03, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 28, 2026
From Contineum Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Contineum Therapeutics, Inc. - Common stock publicly traded?
Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
What is the current price of Contineum Therapeutics, Inc. - Common stock?
The current price of Contineum Therapeutics, Inc. - Common stock is 7.080
When was Contineum Therapeutics, Inc. - Common stock last traded?
The last trade of Contineum Therapeutics, Inc. - Common stock was at 10/16/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap